Controversy Regarding HCV Treatment and HCC Recurrence
Recorded On: 03/08/2017
This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.
Michael D. Leise (Moderator)
Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester. He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.
Amit G. Singal
Dr. Singal completed his GI and transplant hepatology fellowships at the University of Michigan and is currently an Associate Professor of Medicine at UT Southwestern Medical Center in Dallas. He serves as Clinical Chief of Hepatology and Medical Director of the UT Southwestern and Parkland Memorial Liver Tumor programs. He has over 75 peer-reviewed publications, with the majority examining the hepatocellular carcinoma screening process, from risk assessment to early detection to treatment.